JP2023541522A5 - - Google Patents

Info

Publication number
JP2023541522A5
JP2023541522A5 JP2023507550A JP2023507550A JP2023541522A5 JP 2023541522 A5 JP2023541522 A5 JP 2023541522A5 JP 2023507550 A JP2023507550 A JP 2023507550A JP 2023507550 A JP2023507550 A JP 2023507550A JP 2023541522 A5 JP2023541522 A5 JP 2023541522A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
compound
unsubstituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541522A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/071694 external-priority patent/WO2022029138A1/en
Publication of JP2023541522A publication Critical patent/JP2023541522A/ja
Publication of JP2023541522A5 publication Critical patent/JP2023541522A5/ja
Pending legal-status Critical Current

Links

JP2023507550A 2020-08-03 2021-08-03 低分子量タンパク質分解物質及びその適用 Pending JP2023541522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLPCT/PL2020/000066 2020-08-03
PL2020000066 2020-08-03
PCT/EP2021/071694 WO2022029138A1 (en) 2020-08-03 2021-08-03 Low molecular weight protein degraders and their applications

Publications (2)

Publication Number Publication Date
JP2023541522A JP2023541522A (ja) 2023-10-03
JP2023541522A5 true JP2023541522A5 (cg-RX-API-DMAC7.html) 2024-07-25

Family

ID=72193535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507550A Pending JP2023541522A (ja) 2020-08-03 2021-08-03 低分子量タンパク質分解物質及びその適用

Country Status (11)

Country Link
US (1) US20240294489A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188373A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023541522A (cg-RX-API-DMAC7.html)
KR (1) KR20230048373A (cg-RX-API-DMAC7.html)
CN (1) CN116457344B (cg-RX-API-DMAC7.html)
AU (1) AU2021319847A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001956A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186919A1 (cg-RX-API-DMAC7.html)
IL (1) IL300308A (cg-RX-API-DMAC7.html)
MX (1) MX2023001401A (cg-RX-API-DMAC7.html)
WO (1) WO2022029138A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117440948A (zh) * 2021-06-28 2024-01-23 成都分迪药业有限公司 酰胺类化合物及其用途
CN114933584B (zh) * 2021-08-09 2022-12-27 上海贵之言医药科技有限公司 一种二氢-2h-异吲哚酯类化合物
CN116082301A (zh) * 2021-11-05 2023-05-09 上海美志医药科技有限公司 具有降解gspt1活性的化合物及其应用
WO2023085785A1 (ko) * 2021-11-09 2023-05-19 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
AU2022405474B2 (en) * 2021-12-08 2026-08-13 Gluetacs Therapeutics (Shanghai) Co., Ltd. E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) * 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド CK1αおよびDUAL CK1α/GSPT1分解化合物
WO2024096753A1 (en) 2022-11-02 2024-05-10 Captor Therapeutics S.A. Nek7 degraders and methods of use thereof
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
AU2007290407A1 (en) * 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US8927725B2 (en) * 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
IL319363A (en) * 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
JP7258009B2 (ja) 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CA3075813A1 (en) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor sall4 and uses thereof
US10905684B2 (en) * 2018-06-13 2021-02-02 Biotheryx, Inc. Aminoamide compounds
EA202191833A1 (ru) * 2018-12-31 2021-10-11 Селджин Корпорейшн Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида

Similar Documents

Publication Publication Date Title
CN116457344B (zh) 低分子量蛋白质降解剂及其应用
CN109789146B (zh) 趋化因子受体调节剂及其用途
JP2017533922A5 (cg-RX-API-DMAC7.html)
JP2006515587A (ja) 性的不能を治療する方法
CN102083773A (zh) {f-19}标记的l-谷氨酸和l-谷氨酰胺衍生物(ⅲ)、其用途和制备方法
CN110248662A (zh) 一种治疗前列腺癌的组合、药物组合物及治疗方法
EP3784662B1 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
JP2019509986A (ja) トリプトライドのグルコース・コンジュゲート、その類縁体及び使用
JP2022521081A (ja) Hbv感染若しくはhbv誘導性疾患の治療において有用なアミド誘導体
JP2007505044A5 (cg-RX-API-DMAC7.html)
JP2022169780A5 (cg-RX-API-DMAC7.html)
US10077236B2 (en) Azacyclic constrained analogs of FTY720
WO2018068665A1 (zh) 微管蛋白抑制剂
BR112012020377B1 (pt) Uso de um composto ou sal farmaceuticamente aceitável do mesmo e embalagem comercial
AU2021328979A1 (en) Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof
WO2013075199A1 (pt) "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos
RU2004111787A (ru) Ретиноидные агонисты (1), производные алкилмочевины
BRPI0906248B1 (pt) composto, composição farmacêutica para inibir a formação de microtúbulos e método para preparar um composto
JP2023550035A (ja) がん治療におけるmetap2阻害剤及びcdk4/6阻害剤の組み合わせ
CN108473449B (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的砜脒及其制备方法和用途
AU2017355566A1 (en) Inhibitors of mtor-deptor interactions and methods of use thereof
US10093609B2 (en) TAK1 kinase inhibitors, compositions, and uses related thereto
WO2023224128A1 (ja) 線維症の治療又は予防のための医薬組成物
RU2004111789A (ru) Ретиноидные агонисты
RU2800042C1 (ru) Спиросоединения в качестве ингибиторов ERK и их применение